Globus Medical, Inc. $GMED Shares Sold by Kathmere Capital Management LLC

Kathmere Capital Management LLC lowered its stake in Globus Medical, Inc. (NYSE:GMED) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 270,888 shares of the medical device company’s stock after selling 8,447 shares during the period. Globus Medical accounts for 1.6% of Kathmere Capital Management LLC’s holdings, making the stock its 17th biggest position. Kathmere Capital Management LLC’s holdings in Globus Medical were worth $23,651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in GMED. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Globus Medical by 2.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock valued at $375,000 after buying an additional 170 shares during the last quarter. Parallel Advisors LLC raised its stake in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the last quarter. GAMMA Investing LLC raised its stake in Globus Medical by 14.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company’s stock worth $82,000 after acquiring an additional 184 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. Finally, Probity Advisors Inc. lifted its position in Globus Medical by 5.5% during the 3rd quarter. Probity Advisors Inc. now owns 3,792 shares of the medical device company’s stock worth $217,000 after acquiring an additional 199 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the sale, the director owned 10,419 shares in the company, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 35,594 shares of company stock valued at $3,332,253 over the last ninety days. Company insiders own 18.51% of the company’s stock.

Analyst Upgrades and Downgrades

GMED has been the topic of a number of research reports. Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Citigroup reaffirmed a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Barclays upped their target price on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Finally, Royal Bank Of Canada raised their price target on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Stock Performance

NYSE:GMED opened at $86.56 on Friday. The firm’s fifty day moving average is $89.68 and its two-hundred day moving average is $79.88. The firm has a market cap of $11.71 billion, a price-to-earnings ratio of 21.97, a PEG ratio of 2.04 and a beta of 1.05. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The business had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company’s revenue was up 25.7% on a year-over-year basis. During the same quarter last year, the business posted $0.84 EPS. As a group, equities research analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.